Downloaded from http://journals.lww.com/hnpjournal by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 02/15/2022 FEATURES Evaluation of the Effect of Lavender Aroma on Fatigue Among Hemodialysis Patients ■ Elham Rahimi, MSc, RN ■ Asieh Sedighi Chafjiri, MSc, RN ■ Farideh Hasavari, MSc, RN ■ Ehsan Kazem Nezhad Leyli, PhD ■ Maryam Naseri, PhD ■ Masoud Khosravi, MD Fatigue is a complication of hemodialysis (HD). We examined the effect of aromatherapy on fatigue in 62 HD patients. Data were collected using a questionnaire and the Piper Fatigue Scale. It was found that fatigue decreased in the intervention group (P < .05). Lavender aromatherapy is useful in reducing fatigue. KEY WORDS: aromatherapy, fatigue, lavender oil, renal dialysis Holist Nurs Pract 2022;36(2):76–84 Author Affiliations: Faculty of Nursing and Midwifery (Mss Rahimi, Sedighi Chafjiri, and Hasavari and Dr Kazem Nezhad Leyli), Faculty of Pharmacy (Dr Naseri), and Faculty of Medicine (Dr Khosravi), Guilan Uni- versity of Medical Sciences, Rasht, Iran. This article was funded by the Research Vice-chancellor of Guilan Univer- sity of Medical Sciences. The authors express gratitude to the Research and Technology Center of Guilan University of Medical Sciences for funding this article. This article was derived from a master’s thesis on the internal-surgical nurs- ing (ethics code: IR.GUMS.REC.1398.310) in the Faculty of Nursing and Midwifery, Guilan University of Medical Sciences, Rasht, Iran. The authors express their gratitude to the officials and staff at the Research and Tech- nology Center of Guilan University of Medical Sciences, Razi Educational and Medical Center, and the Caspian Private Dialysis Center in Rasht, Iran, as well as all patients participating in this study who have cooperated and participated in this research project. E.R. contributed to conceptualization, methodology, collecting data, and writing initial manuscript; A.S.C, edit data and manuscript; E.K.L., statis- tical analysis; and F.H., M.N., and M.K., the consultations. All the authors read and approved the version for submission. This research involved human subjects and approved by the Guilan Uni- versity of Medical Science Ethical Committee. The Committee provided a reference number IR.GUMS.REC.1398.310. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. The authors warrant that this work contains no libelous or unlawful state- ments and does not infringe or violate the publicity or privacy rights of any third party, libel or slander any third party, contain any scandalous, obscene, or negligently prepared information, or infringe or violate any other per- sonal or proprietary right of others. Each author warrants that the work does not contain any fraudulent, plagiarized, or incorrectly attributed material. Each author warrants that all statements contained in the work purporting to be facts are true, and any formula or instruction contained in the work will not, if followed accurately, cause any injury, illness, or damage to the user. If excerpts (eg, text, figures, tables, illustrations, or audio/video files) from copyrighted works are included, a written release will be secured by the authors prior to submission, and credit to the original publication will be properly acknowledged. Each author further warrants that he or she has obtained, prior to submission, written releases from patients whose names or likenesses are submitted as part of the work. INTRODUCTION Nowadays, the number of patients with end-stage renal disease (ESRD) is increasing. 1 The disease is characterized by irreversible reduction of renal function. 2 Various diseases such as diabetes, hypertension, and polycystic kidney disease cause ESRD. 3 Hemodialysis (HD) as a renal replacement method is the most common treatment option for patients with ESRD. 4 There are more than 1 million dialysis patients in the world, with a prevalence of 25 000 per year. 5 Although HD prolongs patients’ lives, it may cause some problems, such as fatigue, pain, vomiting, sleep disturbance, dyspnea, cramping, and pruritis. 6,7 Among the HD complications, fatigue is the most frequent problem affecting 60% to 97% of patients undergoing HD. 8 Fatigue is defined as a distressing feeling of physical, cognitive, and emotional tiredness. 9 Causes of fatigue in HD patients include anemia, comorbidities, depression, chronic inflammation, nutritional deficiencies, uremic syndrome, dialysis inadequacy, hypokalemia, and sleep disorders. 10-13 Fatigue causes various problems The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Correspondence: Asieh Sedighi Chafjiri, MSc, RN, Department of Nurs- ing, Faculty of Nursing and Midwifery, Guilan University of Medical Sci- ences, Rasht, Iran (a.sedighi6596@gmail.com). Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/HNP.0000000000000501 Copyright © 2022 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. 76